CO2021016606A2 - Methods of administering an anti-cd38 antibody to treat multiple myeloma - Google Patents

Methods of administering an anti-cd38 antibody to treat multiple myeloma

Info

Publication number
CO2021016606A2
CO2021016606A2 CONC2021/0016606A CO2021016606A CO2021016606A2 CO 2021016606 A2 CO2021016606 A2 CO 2021016606A2 CO 2021016606 A CO2021016606 A CO 2021016606A CO 2021016606 A2 CO2021016606 A2 CO 2021016606A2
Authority
CO
Colombia
Prior art keywords
antibody
administering
methods
multiple myeloma
treat multiple
Prior art date
Application number
CONC2021/0016606A
Other languages
Spanish (es)
Inventor
Heloise Audat
Zambrano Frank Campana
Sylvia Marion
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO2021016606A2 publication Critical patent/CO2021016606A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se proporcionan métodos para tratar a un individuo humano que tiene mieloma múltiple que comprenden administrar al individuo 10 mg/kg de isatuximab mediante infusión intravenosa, en donde el volumen de cada infusión de 10 mg/kg de isatuximab es 250 ml. También se proporcionan métodos para tratar a un individuo humano que tiene mieloma múltiple que comprenden administrar un anticuerpo anti-CD38 en ciclos de 28 días, en donde el anticuerpo anti-CD38 se administra en los Días 1, 8, 15, y 22 de un primer ciclo de 28 días, en donde el anticuerpo frente a CD38 se administra en los Días 1 y 15 de cada ciclo de 28 días después del primer ciclo de 28 días; y en donde el anticuerpo anti-CD38 se administra a una dosis de 10 mg/kg o 20 mg/kg.Methods of treating a human subject having multiple myeloma are provided comprising administering to the subject 10 mg/kg isatuximab by intravenous infusion, wherein the volume of each 10 mg/kg isatuximab infusion is 250 mL. Also provided are methods of treating a human subject having multiple myeloma comprising administering an anti-CD38 antibody in 28-day cycles, wherein the anti-CD38 antibody is administered on Days 1, 8, 15, and 22 of a cycle. first 28-day cycle, wherein the CD38 antibody is administered on Days 1 and 15 of each 28-day cycle after the first 28-day cycle; and wherein the anti-CD38 antibody is administered at a dose of 10 mg/kg or 20 mg/kg.

CONC2021/0016606A 2019-05-14 2021-12-07 Methods of administering an anti-cd38 antibody to treat multiple myeloma CO2021016606A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962847825P 2019-05-14 2019-05-14
US201962860739P 2019-06-12 2019-06-12
US201962899088P 2019-09-11 2019-09-11
EP20305223 2020-03-03
PCT/US2020/032754 WO2020232173A1 (en) 2019-05-14 2020-05-13 Methods of administering anti-cd38 antibody to treat multiple myeloma

Publications (1)

Publication Number Publication Date
CO2021016606A2 true CO2021016606A2 (en) 2022-04-29

Family

ID=71094805

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0016606A CO2021016606A2 (en) 2019-05-14 2021-12-07 Methods of administering an anti-cd38 antibody to treat multiple myeloma

Country Status (15)

Country Link
US (1) US20210171650A1 (en)
EP (1) EP3969004A1 (en)
JP (1) JP2022532356A (en)
KR (1) KR20220008305A (en)
CN (1) CN114080233A (en)
AU (1) AU2020274169A1 (en)
BR (1) BR112021022503A2 (en)
CA (1) CA3140034A1 (en)
CO (1) CO2021016606A2 (en)
IL (1) IL287832A (en)
MA (1) MA55967A (en)
MX (1) MX2021013910A (en)
SG (1) SG11202112513YA (en)
TW (1) TW202108624A (en)
WO (1) WO2020232173A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021376374A1 (en) * 2020-11-03 2023-06-29 Sanofi-Aventis U.S. Llc Use of isatuximab for the treatment of multiple myeloma
EP4319770A1 (en) * 2021-04-08 2024-02-14 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and a cd38-targeted antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
SG11202108029XA (en) * 2019-01-28 2021-08-30 Sanofi Sa Methods of treating multiple myeloma

Also Published As

Publication number Publication date
JP2022532356A (en) 2022-07-14
KR20220008305A (en) 2022-01-20
AU2020274169A1 (en) 2022-01-20
TW202108624A (en) 2021-03-01
WO2020232173A1 (en) 2020-11-19
IL287832A (en) 2022-01-01
SG11202112513YA (en) 2021-12-30
CN114080233A (en) 2022-02-22
MA55967A (en) 2022-03-23
BR112021022503A2 (en) 2021-12-28
MX2021013910A (en) 2022-03-11
CA3140034A1 (en) 2020-11-19
US20210171650A1 (en) 2021-06-10
EP3969004A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
CO2021016606A2 (en) Methods of administering an anti-cd38 antibody to treat multiple myeloma
PE20190205A1 (en) USE OF MYOSTATIN INHIBITORS AND COMBINATION THERAPIES
AR105027A1 (en) METHODS OF TREATMENT OF LOCALLY ADVANCED OR METASTASIC BREAST CANCER USING ANTAGONISTS OF THE PD-1 AND TAXAN AXIS
PH12020500555A1 (en) Esketamine for the treatment of depression
AR104771A1 (en) DRY POWDER INHALER
JP2012131811A5 (en)
MD3883606T3 (en) Safe and effective method of treating ulcerative colitis with anti-IL12/IL23 antibody
ECSP22049008A (en) METHODS OF TREATMENT OF SMALL CELL LUNG CANCER WITH LURBINECTEDIN FORMULATIONS
CL2021001389A1 (en) Capsule formulations
MX2023007826A (en) Methods comprising fixed intermittent dosing of cediranib.
AR062779A1 (en) TREATMENT OF MULTIPLE SCLEROSIS (MS)
MX2022005628A (en) Dosing regimen for anti-bcma agents.
AR120399A1 (en) A METHOD OF TREATMENT OF A DLL3 POSITIVE CANCER
CO2020008561A2 (en) Subcutaneous dosage of anti-cd38 antibodies
AR111491A1 (en) METHODS TO TREAT PEDIATRIC DISEASES
AR102903A1 (en) DRY POWDER INHALER
PE20180023A1 (en) METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH BUPROPION AND TRAZODONE COMBINATION TREATMENT
AR125403A1 (en) METHODS FOR THE TREATMENT OF CANCERS
AR115563A1 (en) MUSCLE SPECIFIC MICRODISTROPHIN DELIVERY VIA ADENO-ASSOCIATED VIRUS VECTORS TO TREAT MUSCULAR DYSTROPHY
CO2023017669A2 (en) Advantageous anti-hcv combination therapy
AR114012A1 (en) METHOD OF PROVIDING CELIPROLOL THERAPY TO A PATIENT
AR126183A1 (en) ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY
UA116600U (en) METHOD OF TREATMENT OF ACUTE ISCHEMIC STROKE
PL431290A1 (en) Safe method of administering substances to snails by intravenous injection
JP1745173S (en) pants